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Episode 48: A Mended Heart 
Chris Dall: [00:00:00] Hi, everyone. Before we get started with this week's episode of 
the Osterholm Update, we just wanted to let you know that next Tuesday, March 23rd at 
seven p.m. Central, 8:00 p.m. Eastern, we'll be hosting a live episode of the podcast on 
our YouTube channel. You can tweet us your questions using the hashtag 
#OsterholmUpdateLive. The link to the live stream will be posted in this week's episode 
description. Now to this week's episode of the Osterholm Update. 
 
Chris Dall: [00:00:31] Hello and welcome to the Osterholm Update: covid-19, a weekly 
podcast on the covid-19 pandemic with Dr. Michael Osterholm. Dr. Osterholm is an 
internationally recognized medical detective and director of the Center for Infectious 
Disease Research and Policy, or CIDRAP, at the University of Minnesota. In this 
podcast, Dr. Osterholm will draw on more than 45 years of experience investigating 
infectious disease outbreaks to provide straight talk on the covid-19 pandemic. I'm Chris 
Dall, reporter for CIDRAP News, and I'm your host for these conversations. 
 
Chris Dall: [00:01:07] Over the course of the past week, there's been a great deal of 
media coverage marking the year since the World Health Organization declared covid-
19 a global pandemic. Much of that coverage is focused fittingly on the lives lost and 
devastation wrought by the coronavirus. There's also been a lot of focus on what we've 
learned over the past year. We've clearly learned a lot about the virus and how it 
spreads, sickens and kills people over the past year. But with all that we know, how 
much we really understand this virus? In an interview last June with the public radio 
program Here & Now, right as the second wave of U.S. cases was starting, Dr. 
Osterholm said the following: "I think we all in the public health world have to have real 
humility right now and just admit we don't understand exactly what's happening and that 
we will do our very best to figure it out, to understand it, and to make recommendations 
about what we need to do to move forward with this pandemic." Two surges later, in the 
midst of a decline in cases that's been hard to explain we're facing a potential surge 
driven by variants, can we say that we have a better understanding of exactly what's 
happening? And how does that shape the recommendations we make moving forward? 
The light at the end of the tunnel is getting brighter as more and more people get 
vaccinated, but do we still need that humility in the face of a virus that has thrown us 
some curveballs over the past few months? We'll address all these issues on this March 
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18th episode of the Osterholm Update as we discuss the current state of the pandemic 
and the variants. We'll also answer some questions about covid-19 vaccines and take a 
look at a recent study on physical distancing in schools. And we'll highlight the latest 
pandemic act of kindness from one of our listeners. But first, as always, we'll begin with 
Dr. Osterholm's opening comments and dedication. 
 
Michael Osterholm: [00:02:47] Thank you, Chris. Great to be back with you and it's 
really great to be back with the audience. We welcome you, as I said many times, and 
we'll never forget that you have many opportunities to seek out information on covid-19 
and the issues around it. And we so appreciate having you with us, you, as part of our 
podcast family. These are, in fact, times where we need great humility. And so we'll talk 
more about that in a moment. But I would just start out by saying that if ever there was a 
time in my career in terms of what I know and don't know and how do I share what I 
know and don't know in a helpful way, it's now. This week's dedication is one that 
actually is overdue. And I regret that I haven't made this dedication before because I've 
thought about it and somehow it just didn't seem to hit the top of the list. But this week 
it's now at the top of the list. But it's a very important top of the list. This week I dedicate 
this podcast to those individuals with intellectual and developmental disabilities. They 
make up between one to two percent of our population, and they include individuals with 
attention deficit hyperactivity disorder, autism spectrum disorders, blindness, cerebral 
palsy, moderate to profound hearing loss, learning disabilities, seizures, stuttering or 
stammering and any other developmental delay with or without intellectual impairment. 
All of these, though, are something that is very relevant to the issue of covid-19. And I 
say that because it isn't often appreciated that persons with intellectual disabilities had 
higher rates of coronavirus infection than those without such limitation. In this study, 
they found that those with intellectual disabilities had more than 2.6 times the risk of 
becoming infected. They had 2.7 times the risk for hospitalization and 1.3 times the risk 
for hospital death associated with coronavirus infection versus those without intellectual 
disabilities. It's unclear why this is the case. Is it in fact, in part their need for daily care 
and attending close contact with care providers because? Is it because of less ability to 
comply with public health recommendations, use of shared transportation? Is it because 
of residents of long term care facilities? It's just not clear. But the bottom line is we all 
know loved ones in our lives who clearly are suffering from intellectual and 
developmental disabilities. And now on top of it, we throw covid-19. So this is dedicated 
to all of you. We so, so appreciate the gifts that you are in our lives. Rather than being 
in what some would think of as being a challenge, you're also a gift. So this dedication 
goes to you. And it's in that light that I come back to the topic of light and the good 
news. Yes, we're getting there and today, March 18th, we'll have 12 hours and four 
minutes of sunlight, which is a twenty three minute improvement from just one week 
ago. And now that is two hours and fifty seven minutes more of sunlight than we had on 
December 21st. Isn't it exciting? In the United States we've now gone through Daylight 
Savings Time, so we've got that later afternoon. And it's just, there's a feeling in the air 
that it's getting there. It's getting better. And this summer is when not only will we have 
lots of sunlight, but we are so hopeful and so planning on also having much better days 
in living in a covid-19 world. 
 
Chris Dall: [00:06:49] Let's talk about the current situation in the US and in other parts 
of the world and what we're seeing with the variants. But first, does that comment you 
made in June still apply? Do we understand exactly what's happening with covid-19? 
 
Michael Osterholm: [00:07:05] This is one of those good news, bad news situations. I 
know a lot more about covid-19 than I did last June. And because of that, I know a lot 
less about it. This is a situation where I find that so many people have to have an 
answer that perfectly explains what's happening in our world right now, and they'll come 
up with all kinds of expert opinions or expert facts, I guess some would call it. And a 
number of them, to me, hold no water whatsoever. And we are lacking in an expert 
community today that can say precisely, "This is what we know and why we know it, this 
is what we think might be the case, but these are all the reasons we're not sure, and this 
is what we don't know and we just have to tell you what we're trying to do to find out. 
But we don't know." And as I've said so many times on this podcast, I want you to hold 
me accountable to those very, very same conditions. If I don't tell you what I know 
based on data or facts or experience, then discount it. Hopefully you won't believe 
anything I tell you I don't know about and think that I've shared fact with you because it 
won't be. So I think this is a very important time. I come back to the experience that I 
shared with you in previous podcasts about what happened in November. You know, 
that Fifth Dimension song still keeps playing in my head. This is the dawning of the age 
of the variants. And the variants have completely changed this game for me. We are no 
longer talking about the bottom of the third/top of the fourth inning. We're talking about 
two minutes into the first quarter. It is a whole new ballgame. So while there is clearly 
very good news about vaccines, we are making headway in some places around the 
world, not in all, and we're going to talk about that more later. But we're making 
headway in protecting literally millions of people each day around the world. The 
question is going to be, what will the variants do to that protection? Will it compromise 
it? Will have little or no impact? What's happening with these new viruses that, in fact, 
may challenge us in terms of transmissibility and actual ability to cause serious 
disease? What will they do in terms of minimizing the protective effect of either natural 
infection or vaccine protection? So I am very humble about it. And I wish more of my 
colleagues were because I sometimes find it difficult when I read headlines or I see 
quotes in the media and think, "Now, how could you have said that? What data gave 
you that that information that you could say that?" And I'm not trying to be critical, but I 
think it's as much of our obligation as the people doing the talking to also have the data 
to support what we're talking about. And so, yes, humility right now with this virus is a 
very, very important trait. At the same time, make no mistake, there's a lot we can do. 
It's not like we're sitting here with our arms up in the air saying, "Oh, my, oh, my, the sky 
is falling." No, not at all. There's a lot we can do. But that's in part because we still have 
a lot left to learn. 
 
Chris Dall: [00:10:40] Ok, so let's look at what's going on in the US and other parts of 
the world. What do you make of the current epidemiology of the coronavirus? 
 
Michael Osterholm: [00:10:50] Well, let me begin by just focusing on good news, and 
that is about the vaccines and where we're at, because that'll immediately then apply to 
how do we interpret what's happening with the variants. In the United States specifically 
we are at, as of this week, about 11 percent of our population has been fully vaccinated 
with two doses. An additional 11 percent have been vaccinated with at least one dose 
for a total of 21.7 percent at this point, roughly. When we look at those sixty five years of 
age and older population that is near and dear to my heart because of the fact that they 
are at such a significantly increased risk for serious disease, hospitalization and death 
and right now we have thirty six percent of those individuals who are fully vaccinated 
and we have about sixty four percent who have had at least one dose. Now that again is 
still thirty five percent who haven't had any vaccine, which translates to 20 million 
Americans sixty five years of age and older. That is still the very vulnerable population 
that I worry so much about. So the good news this is happening. I'll comment more 
later, but on a global level, we still are leaving the middle and low income countries 
pretty much out of it. And this is a tremendous challenge, both from a humanitarian 
standpoint, but also from a strategic standpoint of protecting our vaccines. Where we're 
going to see the variants that have the potential to compromise the protection that our 
vaccines provide us, I am convinced is going to come out of this widespread natural 
infection transmission model of the low and middle income countries where we are 
doing little at this point to vaccinate more than just a small portion of that population. So 
that's our challenge. And I believe we should be taking that on for humanitarian 
reasons. But I also believe it is such an important strategic effort that we need to launch 
to see how we can manufacture vaccines, distribute vaccines, get them in people's 
arms around the world, and shut this virus down on the planet, not just in a country, not 
just in a region. The final thing I just want to say to give people a sense of this kind of 
good news, bad news, we're working on the vaccines. Why are we doing that? I don't 
think people realize yet just the full dimensions of what this virus is doing today. Today. 
As we speak here, this week, covid-19 is the number one cause of death in the 
Americas. North and South America, Central America. One third of all the deaths in the 
Americas today are due to covid-19. That hasn't happened since 1918. So when people 
think that the pandemic is waning, it's over with, it's done even when we see lower 
numbers here, for our own Americas it is still an incredible public health challenge. So 
with that backdrop, let me give you a sense of what's happening with variants, because 
they are the complicating factor here that are going to make our future challenging at 
best. I've been talking about the situation with B117, the variant first found in the United 
Kingdom for better part of nine weeks now. And I think some people think, you know, at 
some point just be quiet about it, you know, when is it going to really happen? And we 
did start to see the increase in B117 variant activity in the Americas, particularly in the 
United States, literally about six weeks ago. Now, we have seen in the United States 
where we are doing sequencing, ever increasing proportion of those viruses being 
sequenced are B117. And let me remind you, as a variant of concern, remember, there 
are three kinds of variants of concern. One is more transmission. Two is more serious 
illness. And three is the ability to evade immune protection from either natural disease 
recovery or from vaccine. And in this case, what we're looking at with B117 is the first 
two categories, increased transmission, up to 60 to 70 percent increased transmission 
over previous sars-cov-2 viruses, as well as more serious disease. This week, a paper 
in Nature supported that up to 60 percent increase in severe illness, also much as we 
were talking about the percentage increase in transmission. So what's happened? Well, 
we now see the Helix Dashboard, which is that company that is sequencing these at 
about 46 percent of the cases in Florida as of March 9th are now B117. Twenty five 
percent of the cases in California on March 10th. Thirty eight percent of the cases in 
Texas on March 9th and 40 percent of the cases in Georgia as of March 9th. These are 
areas where we have more of the viruses being sequenced and give us a bit more data. 
All of these are getting there or close to that 50 percent level where in Europe we saw 
countries at that point reaching that same level, showing a significant increase in cases. 
So, you know, we're right at that point. In the meantime, we have seen other areas of 
the country where we don't have the similar set of data regarding the sequencing, but 
suggestive data such as in Michigan, where they have literally gone in one month from 
about 1045 cases reported a day to now over 2223 average cases reported per day. 
And that number is continuing to increase. That has been attributed in at least some 
part, if not large part, to the presence of B117. As part of this Minnesota outbreak we 
are seeing an ever increasing transmission in adolescents, teenagers with spill over 
then into the community. Much of this has been associated with youth sports. For 
example, in this outbreak that has been investigated by both the Minnesota Department 
of Health and local health departments here. And I might add, an absolutely incredible 
piece of work, incredible piece of work by this group. They have found what just several 
weeks ago was an initial outbreak of the B117 and is now spread to four private 
schools. It's now in nine public schools. It's in one child care program. It's involved 18 
hockey teams, four basketball teams associated with three different high schools, three 
club lacrosse teams, one club soccer team, two recreational centers and one fitness 
center. And it's still expanding rapidly. This is the kind of challenge you see, because 
while it's focused yet largely in our younger age population, it's the spillover that occurs 
once it gets into moms and dads, grandpas and grandmas. That's where we have to be 
very concerned about this. And as I said last week, having been in this business for 
forty six years, there are those few times you can look at something happening that 
Mother Nature is doing. You go, "Oh my, how is that happening?" And the dynamic 
transmission that's happening here right now with B117 is unlike anything I have seen 
throughout the duration of this pandemic in terms of transmission. So this is really a real 
challenge. Just to give you some sense of what's happening right now, we're seeing 
over an eighty five percent increase in cases in Minnesota for the last week versus a 
month ago at the same time period. And I think this is, in fact, an example of what is 
going to continue to occur with B117. I'm happy to report that the US government is 
actually taking this situation very seriously and just in the last several days have actually 
made a series of public statements about what they're doing to prepare for the surge 
and how they're ramping up their activities to look at the ability to go into areas that are, 
in a sense, hotspots with B117 with additional vaccine and to try to minimize 
transmission. For example, yesterday a senior White House official said, "Everything we 
do is with the thought in mind that there might be another surge." This, to me, is a really 
important situational awareness. You've heard Rochelle Walensky, the CDC director, 
Tony Fauci, the director of the National Institute of Allergy and Infectious Diseases, all 
sounding the alarm about the issue of making certain we don't put ourselves in harm's 
way. I can't say that strongly enough. Look at the people on here largely, some of you I 
know are recovered, having been infected, some of you have lost loved ones, but many 
of us on this podcast have not yet been infected. And there is no reason we should get 
infected. None of us want to be the person who dies one week before they were 
scheduled to get their vaccine. So now's the time for us to hold out just a little bit longer, 
just a little bit longer. Now is the time for us to do that, and I do see the potential future 
as being so, so much brighter. Let me just add a couple of points of context, though, 
because I think this is really important so that people understand that this is not just a 
bunch of public health people crying wolf. But if we look at some of the countries in 
Europe, remember what's happened in Europe, they had major activity in that 
December/January time period that we did from non-variants. This was their response. 
Lockdown, lockdown. We didn't. They did. And so when B117 started to show its ugly 
face in Europe, spreading from basically the U.K. to other countries in Europe in late 
December, early January, these countries were already in lockdown for the previous 
surge. And so at first B117 really didn't have a chance to take off nearly as much. But 
since that time, that has really changed. Now, I've already shared with you over and 
over again what's happened in England, and they are now literally just beginning to 
open up. The government leaders and public health officials in England have made it 
very clear they will take additional steps again should they see a spike in cases occur 
as they open up. Their hope, like ours, is to get more and more people vaccinated. And 
in this situation, they're further ahead in getting more of the older population vaccinated. 
We still have a ways to go to get that done. What's happening in Germany now? They 
are now seeing a very rapidly increasing occurrence of cases. They've had over a forty 
six percent increase in cases of B117 over the past two weeks, as was stated by one of 
their public health leaders. We have clear signs a third wave in Germany has already 
begun. The latest modeling from their leading Infectious Disease Institute predicts that if 
the increase continues at this rate for the next four weeks, Germany will have a higher 
covid incidence rate than it did at Christmas, its previous peak. So they're very 
concerned even with what they've had in place. For example, most stores have been 
closed in Germany since December 16. Restaurants and bars have been closed since 
November 2nd. They did reopen elementary schools last week and hair salons on 
March 1st. Germany extended their lockdown until March 28th, but are considering 
easing some restrictions in areas with lower infection rates to allow some non-essential 
business to reopen. Again they emphasize easing of restrictions will be quickly reversed 
with an emergency brake if incidence exceeds 50 cases per hundred thousand 
residents for seven consecutive days. So here is a place that's basically been dealing 
with this situation for almost three months. Let me just close with a couple of other 
examples of countries in Europe, which I think really are very instructive on what we 
might expect to see here. Over the course of recent weeks, I've heard over and over 
again from various experts in the media saying that number one, seasonality is now 
critical to the case numbers dropping and that we won't see a surge of cases with B117. 
There's no way they can say that. We still have no evidence that seasonality is playing a 
role in the transmission of this virus. It may one day, but at this point, there's no 
evidence. The peak we saw, as I mentioned before, in January was the peak resulting 
from the major increase in cases in the Sunbelt states from Southern California to 
Georgia. The very same states that, by the way, were on fire in July that gave us that 
first initial large peak. If you look at what's happening in the northern hemisphere, the 
southern hemisphere, absolutely no sense that seasonality is playing any role. I only 
point this out because that would be a convenient way of saying why the case numbers 
are dropping and will stay low. The other one is, is that we have hit herd immunity or 
that we have such protection in the United States from the number of people who have 
been infected. Let me just be really clear about where we sit in the United States right 
now in terms of protection from vaccine and from previous infection. To date, we 
estimate that at most 25 to 30 percent of the US population has evidence of previous 
infection. I have just reviewed several recent papers submitted for publication looking at 
the serology or antibody prevalence of people in the United States. And it is very clear 
that we are no higher than that level. Think of all the pain, suffering and loss that we've 
experienced in the last year just to get to twenty five or thirty percent. We've paid a 
tremendous price and we still potentially have a long ways to go. If you add in the 
vaccination numbers I just gave you about 11 percent of the population being 
vaccinated, 21 plus percent with one dose at least, that adds up basically to 45 to 55 
percent of the population currently protected. I tell you this because two countries right 
now in Europe are experiencing major, major increases. I mean, we're talking about 
exponential growth curves. One is Malta. While that's a much smaller country and their 
numbers are much smaller overall, their peak in mid-January when it was really high, it 
was one hundred and ninety seven cases a day. Now we're seeing actually seven day 
averages of three hundred and seven cases and the number is rising quickly. I mean, it 
is on a rocket ship north. When you look at them, they have had almost 17 percent of 
their population has had at least one dose. It's not that far off from ours. And more 
importantly, when you look at what's happened, they have had a history of lots of 
infections in Malta already. So they are, in a sense, very similar to us of what we might 
expect to see with protection from previous infection and vaccine. And yet seeing, and 
this by the way was all B117. It's very clear that B117 is driving this particular increase. 
If you look at the rest of the world as a model, you can see what is happening. And so 
from that perspective, I just want to really emphasize why it is we must pay such close 
attention. Let me close this section by commenting on the variants of concern that are 
other than B117 and the ones that we've been most concerned about. And I have to 
start at the top of the list, which is the P1 variant, the one we've seen in Brazil. Right 
now Brazil is a total house on fire. We are seeing major increases in cases literally 
every day there. Their seven day average and their mid-January peak was about 54.6 
cases. This was before really P1 started. This past week it's now up to 71.4 thousand 
cases per day and it's climbing really quickly. P1 is by far the most important of the 
variants we're seeing there. This is the one that has the ability to evade immune 
protection of vaccines and in previous immunity from natural infection. How much it 
evades it is still unclear. There's now increasing evidence that also it may be much 
more infectious and causing more serious illness. So it would, in a sense, include all 
three of the buckets that we talk about with variants of concern. We're seeing major 
increases in hospitalization in Brazil such that they are by their own declaration in crisis. 
In the southern states of Rio Grande do Sul, ICUs are so overloaded that the largest 
public hospital treating covid-19 patients in the state capital Porto Alegre said Sunday it 
was forced to close its doors to any new patients. It just can't take them. This is being 
played out in a number of locations through Brazil. What will happen with P1? We don't 
know. Will we see it coming to our back door? Surely it's here. How much will it spread? 
We don't know. We're seeing it now take off in Uruguay. We're seeing it take off in 
Paraguay. One of the reasons why the Americas, as I mentioned earlier, is such a 
critical issue. So this is one to stay tuned on. We often get asked questions about 
variants of concern in Africa. We haven't had a lot of information coming out of there. 
However, we're now seeing in Ethiopia a rather substantial increase in cases in what's 
happening there. And cases are rising quickly in countries like Libya, Kenya, the Ivory 
Coast and Guinea. So while the data are very limited in what's happening in Africa, it is 
clear that there are an increasing number of infections there that we need to be 
concerned about. 
 
Chris Dall: [00:30:06] So, Mike, do we know anything more about the New York and 
California variants that have been reported? 
 
Michael Osterholm: [00:30:12] We have heard a lot about variants of concern that 
originated right here in the United States, most notably one was called the California 
variant B1429 and B1427. And I think the data right now on those which have been 
refined over the past several weeks, they find that they may be slightly more infectious 
or transmissible, but the data still are inconclusive. They are not main drivers of 
transmission like we're seeing with the B117. The New York variant is more interesting 
and likely of importance. There are now two sub lineages of it, with one carrying what 
we call the E484K mutation, the one that is so important with P1 and B1351, the ability 
to evade immune protection. So I think this is one that I would call it a variant under 
investigation, but it could turn out to be a very significant variant here in the United 
States. 
 
Chris Dall: [00:31:14] So, as you noted, the vaccine rollout continues to pick up steam 
here in the United States, but there's been a pause in some European countries due to 
reports of blood clots in a small number of recipients of the AstraZeneca vaccine, which 
has not yet been authorized in the US. Is this an example of the concern you've raised 
on the podcast in the past, health issues that you would normally see in a population 
that are now being linked to vaccination? 
 
Michael Osterholm: [00:31:40] Any time you see a health condition that occurs 
coincidental with a vaccine, you at least have to take a look and say, "Is this likely or is 
this possible that it could be associated with the vaccine itself?" So no one wants to 
miss or dismiss some kind of a health condition. But at the same time, we have to 
understand there are many, many health conditions that will occur coincidental to 
getting a vaccine. Let's take the situation right now that's happening with the 
AstraZeneca vaccine in Europe. This all began when there were four cases of blood 
clots in abnormal bleeding in four individuals in Norway. All were under 50 who received 
the vaccine. Of the four individuals, two of them died from brain hemorrhages and the 
other two were hospitalized. At that point, that created a great deal of news attention. 
And other countries in Europe started looking at this. As of today, there have been 19 
countries that have decided to delay any further use of the AstraZeneca vaccine, 
despite the fact that the European Medical Authority, the FDA basically of the E.U., and 
the World Health Organization have said do not suspend the program at this time as 
there is no conclusive data that these are really related to the vaccines. If you hear that, 
you say, "Well, how can that be the case? You know, look at what's happening here." 
Well, let me just back up and give some context. If you look at the United States and the 
roughly three hundred and thirty million people we have, every year between three 
hundred thousand six hundred thousand people develop these similar blood clots, 60 to 
100 thousand Americans go on and die annually from this type of thromboembolism. 
Looking at those numbers and extrapolating out to the fact that every day we're 
vaccinating now about two million people. Based on this estimate I just gave you, you 
could expect about one thousand to two thousand of these blood clots to occur in the 
US population every day. If you assume right now that the US has two hundred and fifty 
three million adults, so basically every day about 2.3 million or about one percent of the 
adult population is getting vaccinated. If you take one percent of that normal one 
thousand to two thousand daily blood clots, that's 10 to 20 a day that would occur on the 
day of your vaccination and occur the next day and the next day and the next day. So 
the challenge is, if you do have a risk of some adverse event like this blood clot, how 
would you know? Would you have to see a very sizable increase in the number of cases 
and the answer is yes, that's the challenge we have. So today what you're seeing 
happen is out of an abundance of caution, government officials are basically, in a 
sense, overruling the public health officials and saying we are going to stop the program 
because that's what is politically expedient in light of people not wanting to get blamed 
for having some problem occur. But at the same time, they are undermining 
dramatically vaccine confidence and people who are not getting vaccinated will not be 
protected. And the risk of dying from covid-19, even if there were some slight increased 
risk with this vaccine, is substantially higher from covid-19. So I am very sympathetic to 
the concerns of wanting to know is there some risk, increased risk specifically, with 
getting vaccinated and having these thromboembolisms. But at the same time, 
understanding that by not vaccinating, people are also put at high risk, particularly as in 
many cases in Europe we're seeing this B117 surge and people at risk. So I commend 
the EMA and the WHO for the rapid response. They're having meetings this week. I can 
only hope that some countries are going to reconsider quickly. I understand that that 
may be in the works right now for several other countries that they are going to 
reconsider their bans on the vaccine. And at this point, the British health officials have 
said very clearly in their extensive look see at this in their country, they have seen no 
evidence of increased risk. So stay tuned. But I feel quite confident, based on the 
information I've seen to date, is that this is not a cause and effect kind of event. And let 
me just remind everyone, I shared this with you before in previous podcasts in some 
months ago, if we were to vaccinate one million, 55 to 64 year olds today, one million, 
we would expect in the next week 170 of those individuals to die by whatever cause, all 
cause mortality. Just a straightforward actuarial table kind of a calculation. Imagine in 
the week after someone might have been vaccinated and they die. How many family 
members would immediately connect that vaccine with that death almost without regard 
to what caused it? That's the challenge we're up against right now. And we must do a 
much, much better job of trying to share the information with the public about how do we 
determine when there is an increased occurrence of an event associated with 
vaccination? And when is it just part of the routine events of life? 
 
Chris Dall: [00:37:39] Has there been any movement that you're aware of on the issue 
of extending the interval between the first and second doses of the covid-19 vaccine 
here in the United States? 
 
Michael Osterholm: [00:37:49] There has been. Actually I personally have had 
conversations with some senior White House leaders in this area about this in the past 
week. And now that they're beginning to see the whole surge issue of B117 as a 
possible reality, everyone's talking about what else can be done. And so I don't know 
what will happen. Recall that we laid out four different scenarios that would help us get 
more vaccine to those who are sixty five years of age and older. One was just target it. 
Right now we are basically opening up vaccine to almost anybody and everybody on a 
given state wide basis. Governors are feeling the need to do that, even though vaccine 
isn't going to be available at any larger quantity for some time. They're doing that. Well, 
when you do that, what happens? You take vaccine away that could possibly go into 
those 20 million people 65 years of age and older. Again, where the most severe 
disease, and again, where the hospitalizations and deaths are going to occur. So that's 
number one is just target vaccine to that group. Two, do the delayed dose for weeks, 
eight, 10 weeks till we get more vaccine and we get through this possible surge. Three, 
stop giving second doses to people who have already been infected and then 
vaccinated. We have clear and compelling data that show that they are protected in a 
very, very high level of protection after one dose after natural infection. Use the second 
dose for others. Finally, is the issue of why are we still continuing to use the high dose 
Moderna vaccine at one hundred micrograms when we know 50 will work just fine? And 
boy, wouldn't that be great if we could double the Moderna vaccine availability. So I'm 
hopeful that we're going to continue to have more discussion of this. But every day we 
waste is a day that we can't get more of these individuals vaccinated. And I've heard 
from some of you about how you feel like, wait a minute, we've got to take care of 
people under sixty five of those who from any number of different risk categories that 
are surely deserving. We want you to get vaccinated. As I've shared with you, it's in the 
document that we produced, the CIDRAP viewpoint. We're just talking about trying to 
save the most number of lives. And the way to do that right now would be to target as 
many people as possible sixty five years of age and older. And don't waste a day after 
you have more vaccine and you get them vaccinated to get others younger than that at 
risk, whether it be race, ethnicity, occupation, underlying health conditions, get them 
vaccinated. But get those sixty five years and older vaccinated first. 
 
Chris Dall: [00:40:32] So let's stick with the vaccines here, since we've gotten several 
questions about them from our listeners. One listener, Lisa, wanted to know whether 
you can get or spread covid-19 after vaccination and how much protection the vaccines 
offer against the different variants. You mentioned B117 earlier, what do we know about 
that, Mike? 
 
Michael Osterholm: [00:40:50] We have surely been challenged by the issue of once 
you're vaccinated, in this case, two doses, one dose depending on which vaccine you're 
getting, why do you need to continue masking? Why do you need to continue to worry 
about yourself being infected? And those are legitimate questions. And we've talked 
about those here on this podcast. We're going to continue to talk about those here on 
the podcast. I think the really important message to send here is, is that what data we 
have doesn't at all suggest that one can be infected once vaccinated with an 
asymptomatic or very mild infection and spread it to anyone else. So I think that one 
really, I'm feeling more confident about all the day. I did feel confident months ago, but 
even more so now. So I don't think that's a problem. As far as the variants, the P1 and 
the B1351, those that do evade immune protection, you know, we're still trying to figure 
that out. Just how much does it reduce our protection? We do know from the vaccine 
trials that there was some protection against severe disease, hospitalization and death. 
That's really good news even in the face of that variant. But with what we've seen in 
Brazil in particular, we still have questions. So we're going to have to hold on to 
understanding what B1351 and P1 mean. The important message to get across now, 
however, though, is it to B117 variant, the one that's literally on top of us right now, is in 
fact vulnerable to our vaccines. They're very protective against that variant. And that's 
why we need to get as many people vaccinated as possible. 
 
Chris Dall: [00:42:29] So, Mike, here is an issue that is of interest to parents across the 
country. Many school districts around the country are reopening for in-person learning. 
And a study came out last week that suggested three feet of distance between students 
may be as safe as six feet, which is what the CDC recommends. What did you make of 
this study? 
 
Michael Osterholm: [00:42:49] Well, it surely has received a lot of attention and let me 
just try to put it in context. This paper came out of the Harvard Medical School with a 
very distinguished group of researchers. And what they looked at was the transmission 
of sars-cov-2, the virus causing covid-19 from asymptomatic and pre symptomatic 
individuals in health care settings who actually had medical masks on and eye 
protection. Because they use genetic sequencing they could actually demonstrate with 
certainty that Person A infected Person B and under the conditions with which that 
occurred. And they described three different instances where despite medical masks 
and eye protection transmission occurred. Even if the person themselves were masked 
who was infected. And this shouldn't be a surprise, because as we've shared on this 
program before, medical masks can reduce your risk, but they don't stop the aerosol 
transmission potential because so much leaks out. And this paper, which I hope 
everyone will read, we will put this on our website for a link, really gives people, I think, 
the information that is important to understand. If a medical mask in itself was not 
enough to stop transmission from somebody wearing it who is infected or someone who 
was wearing it who is not infected, who, by the way, had an eye shield and still got 
infected, it just demonstrates how infectious this virus is. So when this paper came out 
on the three feet, six feet, which also came out of a group in Boston, it was very clear to 
many of us who deal with this issue that it had a very, very faulty design. And frankly, I 
think yields virtually no useful data that we can address relative to the safety of three 
versus six feet. First of all, six feet and three feet all correspond to the concept of 
droplets, these big particles that they fall out within six feet. No one suggests for a 
moment they fall out within three feet. Well, we've already said droplets really don't 
necessarily play the major role. Aerosols do, which go much, much further than six or 
10 feet. So the whole issue of addressing three versus six feet is almost nonsensical to 
me. It really makes little to any sense. You would expect the rates of disease to be the 
same for two, three, four, five, six, seven, eight feet apart. Because one, is if I'm in that 
setting, the aerosols are going to spread much further than three or six feet. Number 
two, no one has talked about time. So even if I have a face cloth covering down, that 
does reduce my potential exposure by 20, 30 percent. If I'm in there for hours at a time, 
that basically doesn't cover me for that. Nothing was there about time. The third thing is 
you can say, "Well, but we didn't see all this widespread transmission." Well, we have 
said all along we do not understand why, this is the humility piece again, why kids, 
particularly eighth grade and younger, but even a bit older, we don't see the same level 
of transmission that we see in the rest of the community. This study, had it been done 
when you did no distancing whatsoever, you could be shoulder to shoulder, with or 
without a mask on, you would still find the same information, basically, because, in fact, 
there was so little transmission occurring in schools with kids. So I think that's an 
important point. But the final piece of it is the measurement. I have heard from many 
teachers who have been unable to keep kids three and six feet apart and keep them in 
a way that you can say consistently, "They were only three feet apart or they were only 
six feet apart and always were able to maintain that". So this paper makes no biologic 
sense. I think it has major study design challenges. And I think it would be really 
unfortunate if we now highlight this three/six feet issue, particularly now that B117 is 
coming. There we are seeing transmission in kids in a major way and transmission that 
is not going to be interrupted by a three or six foot barrier as such with a cloth face 
covering on being in the same classroom for hours and hours. So you've heard me on 
this podcast over the course of recent weeks, go from a proponent of kids in school in 
that setting where a pre-B117 environment meant little transmission to one now where 
we have to entertain that. And I think the outbreak right here in Minnesota is clearly 
demonstrating that, in fact, kids together, regardless of how close, are transmitting the 
virus. So I wasn't at all enamored by this paper. And I hope that it does not lead to major 
policy changes in this country, I think would be a major mistake. 
 
Chris Dall: [00:48:01] So now to our acts of kindness update, which always brings a 
smile to our faces. This week we have an act of kindness from a listener here in 
Minneapolis. Can you share with the audience, Mike? 
 
Michael Osterholm: [00:48:13] Well, each week when we look through the acts of 
kindness that have been submitted to us, it's a very moving experience. And it seems as 
if it only gets more moving with time. If you're going to sit down and read these, you 
better bring a box of Kleenex with you. And this week's was no different. This one 
comes from Karin Jacobsen. Notice I mentioned her last name and you'll see why in a 
moment. Karin is from the Twin Cities area here. She's a jewelry designer and maker. 
Well known, very accomplished, beautiful work. And she wrote an email which I will take 
some bits and pieces out of it, not all the whole thing. But she said, "Like many listeners, 
I was called to be part of the pandemic of kindness and as a jewelry designer and 
maker, have found a way that fits my skillset. I have designed a pendent called the 
mended heart pendant, and all the proceeds from the sale of these pendants will be 
donated to the Front Line Families Fund. I'm hoping that it will be a reminder to all who 
wear them of the importance of front line health care workers of their hard work and 
sacrifices over the past year. At the same time, I am glad to be able to donate the 
proceeds of the sales to such a terrific non-profit. There is nothing that can make up for 
these families profound loss. But ensuring better access, resources and scholarships 
can at least keep a tragic situation from getting so much worse." Karin has designed 
what I would call, as much as the jewelry piece of the pandemic. And you must see this 
heart, it is simply remarkable. Just know that in partnership with her retails, Karin has 
committed to meticulously crafting beautiful art, jewelry and wedding rings. All of her 
work is hand fabricated in her studio in Minneapolis and focuses on ethically sound 
materials such as recycled metals and gemstones that are fair trade, recycled, 
domestically sourced. So I urge you to consider taking a look at it. The link is on our 
website. Know that the proceeds, all of them are going to go to the Frontline Families 
Fund, that fund that we helped start to take care of the family members of health care 
workers who have died from covid-19. And also, I hope you'll go visit Karin's website 
just to look at the beautiful jewelry that's there. So Karin as an act of kindness, I can't 
begin to explain how much this means to us at CIDRAP. I know many, many individuals 
on this podcast today are going to also feel the very same when they see your piece of 
work. I also would urge you all in that same light to go back and consider to download 
Vaccinate With Love, the Peter Lake wonderful anthem for a vaccination that was in our 
forty fourth episode done on February 18th. He too is donating the proceeds of any 
downloads that occur with that song to the Frontline Families Fund. And so you artists 
who are so amazing with hearts as large as the world. Thank you. I can't tell you how 
much it means and Karin thank you in particular for your beautiful work and the 
message that it sends to all of us around the world. We must and can support our 
mended hearts. 
 
Chris Dall: [00:51:54] And a reminder to our listeners that if you want to share your 
pandemic act of kindness with us, please email us at OsterholmUpdate@umn.edu. Your 
closing thoughts today, Mike? 
 
Michael Osterholm: [00:52:07] As I've done in the past several weeks, I have gone 
back and revisited the vault of dedications and some have particular meaning that I 
think are worth bringing back for a second go round. And given where we're at right 
now, given the fact that we've got to get through these next weeks, we've got to get 
people vaccinated. Remember, we don't want anyone on this podcast to be the person 
who dies one week before they were scheduled to get their vaccine. We are not going 
to let that happen collectively as a family. We're not going to let that happen and we 
don't have to. But it's going to take us helping each other and it's not going to be easy 
for the next few weeks. I know that. So I pulled this song back out as a, you might say, a 
tribute to that very mindset. This was played originally on Episode 13, way back last on 
June 24th. It was a hit written by Bobby Scott and Bob Russell. It was originally 
recorded by Kelly Gordon in 1969. And then later that year, The Hollies recorded it. It 
was of note that Russell was dying of lymphoma at the time that he wrote the song and 
literally finished it just before he died. The title He Ain't Heavy, He's My Brother has a 
very special meaning. In the 1940s, these words were adopted as a slogan for Boys 
Town Children's Home. Father Ed Flanagan, who began Boystown, noted that he first 
heard those words in 1918 as one of the youthful residents said to him as he was 
climbing the stairs with a boy on his back. The boy carried his brother, who had had 
polio and was in leg braces, and when Father Flanagan asked him about the moment, 
the brother looked at him and said, "He ain't heavy. He's my brother." So today, I'm 
going to take the license to alter a line or two in this lyrics, but I think that the meaning 
will be equally clear and hopefully compelling. So here it is. "He ain't heavy. He's my 
brother and my sister. The road is long with many a winding turn that leads us to who 
knows where, who knows where. But I'm strong, strong enough to carry him or her. He 
ain't heavy. He's my brother. He ain't heavy. She's my sister. So on we go. His welfare 
is my concern and her welfare is my concern too. No burden is he or she to bear. We'll 
get there for I know, he and she would not encumber me. He ain't heavy. He's my 
brother. She ain't heavy, she's my sister. If I'm laden at all, I'm laden with sadness that 
everyone's heart isn't filled with the gladness of love for one another. It's a long, long 
road from which there is no return. Well, we're on the way to there why not share? And 
the load? It doesn't weigh me down at all. He ain't heavy. He's my brother. She ain't 
heavy. She's my sister. He's my brother, she's my sister, he ain't heavy, he's my 
brother, she ain't heavy, she's my sister." Thank you again, all of you, for being with us 
this week. A lot of information to cover. I'm sorry we don't have more time to get into 
many of the other questions that you asked. Great questions. Just be safe. This time 
that we're coming upon is going to pose some new challenges and new risk. Just hang 
in there a little bit longer, just a little bit longer. We're going to get through this. Days are 
getting lighter. To our colleagues and friends and family members in the Southern 
Hemisphere. I'm sorry. We're trying to ship as much sunlight as we can across the 
equator to you, just know your turn will come soon and just be kind. Be patient. Be safe. 
Look for the facts, be humble. And just remember, he and she ain't heavy because 
they're our brothers and sisters. 
 
Chris Dall: [00:57:04] Thanks for listening to this week's episode of the Osterholm 
Update, if you're enjoying the podcast, please subscribe on your podcast platform of 
choice and write a review. And be sure to keep up with the latest covid-19 news by 
visiting our website, CIDRAP.umn.edu. The Osterholm Update is produced by Maya 
Peters, Cory Anderson and Angela Ulrich are our researchers, and Randy and Eric 
Olson are Dr. Osterholm's story consultants. 
 
